The Method – Exposure Method

The Method

Most of what gets sold as "wellness" doesn't work. Or works at doses no one actually takes. Or works for reasons the marketing gets wrong.

Exposure Method exists because there are four categories of stressor where the mechanism is real, the research is mature enough to act on, and the equipment can be evaluated on specs instead of vibes. Cold. Heat. Oxygen. Light.

This page lays out what each one does at the cellular level, who established it in the research, what dose people actually run, what evidence weight sits behind each claim, and the language we use when we talk about it. Read it once and you'll be able to walk into any conversation about recovery hardware and tell the difference between a brand that's read the papers and a brand that's read the marketing.

The standard for our shelf: a product earns space here when the supplier can articulate mechanism, cite the research behind their dose, and tell you what their device doesn't do.

How we weight the evidence

Not every claim on this page has the same strength behind it. We grade the evidence using established academic frameworks — GRADE methodology (the WHO and Cochrane global standard) and Oxford Centre for Evidence-Based Medicine Levels of Evidence — and we tag each finding with one of four composite weights:

  • [A] Strong — multiple randomized trials, large samples, replicated across independent labs. Confidence is high.
  • [B] Moderate — solid studies, but smaller samples or observational design. Confident the effect is real; uncertain about exact magnitude.
  • [C] Emerging — early studies suggest the effect, but the field is still building toward consensus.
  • [D] Mechanism-only — the biological mechanism is plausible, but human outcome data is limited or based on animal models. Take it as a hypothesis worth testing, not an established fact.

Why this matters to you: most of the recovery-equipment evidence base is currently in the [B] to [D] range. Some claims (KIHD sauna cohort mortality reduction, hair regrowth from photobiomodulation, cold's hypertrophy attenuation when timed wrong) are well-supported [A] or [B] tier. Other claims (mild HBOT outcomes at 1.3 ATA, infrared sauna long-term outcomes, transcranial PBM for mood) are still emerging [C] or mechanism-only [D]. We label every major claim on this page so you can calibrate trust.

This is not a proprietary system. The methodology is a faithful application of GRADE and Oxford CEBM. The brand value is that we apply it transparently — most recovery-equipment retailers do not.

Cold Exposure

The acute sympathetic activation pathway. Cold water at the right temperature for the right duration triggers a cascade no other modality replicates.

The mechanism

Submersion at 38–50°F drives an immediate sympathetic nervous system response. Within seconds, norepinephrine spikes 200–300% above baseline and stays elevated for hours after exit. Dopamine elevates approximately 250% and sustains for ~3 hours [D: Šrámek et al. 2000 — a small Czech study often cited, replicated less than the citation count would suggest, but the directional finding is consistent across follow-up work (LeBlanc 1978; broader cold-pressor literature)].

The same exposure activates brown adipose tissue (BAT) — metabolically active fat that burns glucose and lipids to generate heat via non-shivering thermogenesis [C: Søberg PNAS body of work]. Cold shock proteins, particularly RBM3, upregulate; these are neuroprotective and linked to synaptic preservation in mouse models [D: Peretti et al. 2015 Nature, mechanism cascade extended by Bastide 2017 (RTN3) and Preüßner 2021 (ASO therapeutic translation) — strong mechanism, human outcome translation still emerging].

After exit, the parasympathetic rebound drives the calm, focused state practitioners describe as the "afterglow." This is not in your head. It's a measurable autonomic shift [B: documented across the cold-pressor and HRV literature].

The research

Susanna Søberg (Copenhagen) ran the cohort and laboratory studies that suggested the minimum effective weekly dose for BAT activation: roughly 11 minutes total per week distributed across multiple sessions [C: based on Søberg's body of work — small samples (under 30 participants per study), directionally consistent]. Her framework distinguishing adaptation (cold-finish) from relaxation (warm-finish) comes from observing the two physiological response patterns.

Andrew Huberman (Stanford) synthesized the deliberate cold exposure literature in Huberman Lab Episode 66. His framing of cold as an SNS protocol — not a wellness modality — is the cleanest public summary in the space. The synthesis itself is not independent evidence; it pulls from Søberg [C], Kox [B], and the cold-pressor literature [B/D].

Pieter Kox and colleagues at Radboud University Medical Center established that voluntary sympathetic activation under cold is real and measurable [B: Kox 2014 PNAS PMID 24799686, well-designed RCT with biomarker endpoint]. This research, not Wim Hof's popularization, is what the mechanism actually stands on.

The hypertrophy caveat is well-replicated: Llion Roberts and colleagues (2015) demonstrated that cold water immersion within ~6 hours after strength training attenuates muscle protein synthesis and blunts hypertrophy adaptation [B trending A: Roberts 2015 + multiple replications]. If you train for strength, cold has to go on a separate day or hours later.

The protocol

  • Temperature: 38–50°F
  • Duration: 1–5 minutes per session
  • Weekly dose: ~11 minutes total, 2–4 sessions [C: Søberg-derived guideline; observational extrapolation, not RCT-tested at the home-protocol scale]
  • Timing: Morning preferred — aligns with circadian dopamine and won't disrupt sleep
  • Strength training: Separate cold from lifting by 6+ hours, or place on non-lifting days [B trending A]

The vocabulary

Hormesis — adaptive response to controlled stress. Cold shock proteins (RBM3) — proteins upregulated by cold that protect neurons in mouse models. Brown adipose tissue (BAT) — fat tissue that burns calories to generate heat (different from regular "white" fat). Non-shivering thermogenesis — BAT-driven heat production without muscle contraction. Norepinephrine response — the surge of an alertness-related hormone during cold exposure. Deliberate cold exposure — Huberman's term for cold as a protocol, not a wellness modality.

What we look for in a cold supplier

Temperature precision and stability matter more than maximum cold. A unit that holds 39°F ±0.5° hits the therapeutic window every session. A unit that drifts 35°F to 48°F doesn't. Chiller pull-down rate, BTU capacity, filtration system, and insulation R-value are the specs that separate hardware from theater. We require suppliers to cite the research behind their dose claims, weighted per established frameworks (GRADE / Oxford CEBM). We don't carry products that can't tell you all four.

Heat Exposure

The cardiovascular stress proxy. Heat sessions deliver hemodynamic load comparable to moderate exercise without the mechanical wear.

The mechanism

Sustained core temperature elevation triggers heat shock proteins (HSP70, HSP90) — molecular chaperones that fold proteins correctly and repair denatured ones [B: well-established physiological mechanism]. Plasma volume expansion follows repeated sessions: the body retains water and sodium to manage thermal load [B: Scoon 2007 documented 7.1% plasma volume increase + endurance benefit; replicated mechanism].

Heart rate climbs to 100–150 bpm during a 20-minute session. Nitric oxide release drives vasodilation [B: Brunt 2016 J Physiol PMID 27270841, RCT, hot water immersion as proxy]. BDNF (brain-derived neurotrophic factor) elevates, supporting neurogenesis [B: replicated across heat-exercise literature]. Growth hormone spikes acutely post-session, particularly with multiple sessions in a single day [B: documented physiological response].

The "sweat detox" claim is weaker than the wellness industry implies. Liver and kidneys do >95% of the clearance work. Sweat carries trace amounts. We don't make detox claims about heat exposure [F: detox claim has no mechanistic basis at the magnitude marketed].

The research

Jari Laukkanen (University of Eastern Finland) led the KIHD study — 2,300+ Finnish men tracked over 20+ years [B: Level 2 prospective cohort, n=2,315, JAMA Internal Medicine 2015 PMID 25705824]. Subjects with 4–7 sauna sessions per week showed hazard ratios of approximately 0.5 for all-cause and cardiovascular mortality vs. 1 session per week. The dose-response is striking. The data is observational, not RCT-confirmed — "sauna causes lower mortality" is overclaim; "frequent sauna users in the KIHD cohort showed lower mortality" is accurate. Extensions across hypertension (Zaccardi 2017), respiratory disease (Kunutsor 2017), and dementia confirm the dose-response across multiple endpoints.

Rhonda Patrick has produced the most thorough public synthesis of the sauna literature through FoundMyFitness. Her reports are the reference layer for anyone evaluating heat protocols at depth.

Charles Raison (University of Wisconsin) led whole-body hyperthermia trials for major depressive disorder [B: Raison 2016 JAMA Psychiatry PMID 27172277, single sham-controlled RCT with sustained 6-week effect]. The IL-6 cytokine mechanism layer was extended by Flux 2023 [C]. The depression-as-inflammation framework intersects with the heat literature in ways still being mapped. Home sauna at lower thermal load extrapolates from this clinical-trial dose; treat as mechanism-plausible mood support, not depression treatment.

The protocol

  • Traditional Finnish sauna: 174–194°F, 15–20 minutes per session, often multiple sessions with cool-down between [B: aligned with KIHD-cohort exposures]
  • Infrared sauna: 120–150°F, 30–45 minutes — lower ambient, longer duration. Whether infrared at this temperature reliably reaches the core-temperature elevation that drives the documented Finnish-sauna outcomes is less well established. Many infrared sessions don't reach the ≥38.5°C core temperature threshold the Brunt 2016 vascular-adaptation literature depends on [C for acute physiology; D for long-term outcomes — no KIHD-equivalent infrared cohort exists]
  • Frequency for KIHD-associated mortality outcomes: 4+ sessions per week
  • Hydration: Aggressive — water plus sodium replacement, not water alone
  • Strength training: Conservative call is to separate heat from lifting by ~6 hours, similar to cold, though the evidence is less developed

Honest disclosure for men in conception planning: Regular Finnish sauna use causes reversible declines in male sperm count and motility [C: Garolla 2013 Hum Reprod PMID 23427234, n=10 small but well-controlled, effect reversible 6 months after stopping]. The same study measured testosterone directly and found no change — the widely-circulated "sauna boosts testosterone" claim is not supported by direct measurement.

Medication interactions to know. Sauna interacts meaningfully with beta blockers, calcium channel blockers, ACE inhibitors / ARBs, nitrates, diuretics, anticholinergics, and some antidepressants. If you take any of these and plan regular sauna use, talk to your prescribing physician.

The vocabulary

Heat shock proteins (HSP70, HSP90) — cellular repair proteins activated by heat. Plasma volume expansion — the blood's water-and-salt volume increases with repeated heat exposure. Hormetic heat stress — controlled heat as adaptive stressor. Near-infrared (NIR) — ~700–1400nm wavelength range. KIHD cohort — the Kuopio Ischemic Heart Disease cohort, a 20+ year observational study of Finnish men's health habits. BDNF — brain-derived neurotrophic factor, a protein that supports neuron growth.

What we look for in a heat supplier

For traditional saunas: wood species (Western red cedar, hemlock, aspen, Nordic spruce), heater type, and warranty on heating elements. For infrared: wavelength distribution (NIR/MIR/FIR ratio), EMF readings at occupant position (third-party tested, not manufacturer-claimed), and panel coverage relative to bench footprint. Heat-up time matters for daily use. We require suppliers to cite the research behind their dose claims, weighted per established frameworks. We don't carry infrared units that can't produce third-party EMF data, and we don't permit suppliers to cite KIHD mortality figures on infrared product pages — the two modalities are not equivalent in the outcome literature.

Oxygen Exposure

Pressure-driven oxygen saturation. Hyperbaric oxygen exposure forces dissolved O2 into plasma at levels not reachable through breathing alone.

The mechanism

Atmospheric pressure determines how much gas dissolves in liquid. This is Henry's Law. Increase the pressure on someone breathing oxygen, and you saturate the plasma — not just the hemoglobin — with O2. Tissues then receive oxygen via diffusion gradient, reaching areas where blood flow is compromised or capillaries are damaged [B: well-established physiological mechanism].

Downstream:

  • Stem cell mobilization — endothelial progenitor cells release from bone marrow at 3–5x baseline after HBOT sessions [D for consumer-chamber relevance: the 3–5x figure is from Thom 2006/2011 work conducted predominantly at 2.0+ ATA. Whether consumer mild-HBOT chambers at 1.3–1.5 ATA deliver the same magnitude of EPC mobilization is not directly established by 1.3 ATA-specific mechanism trials]
  • VEGF (vascular endothelial growth factor) upregulates, driving neovascularization [B at hard HBOT pressures]
  • Mitochondrial biogenesis — more mitochondria per cell [C: mechanism-evidence at hard HBOT; less clear at consumer pressures]
  • Hyperoxic-hypoxic paradox — Efrati and colleagues propose that cycling between high O2 and ambient triggers adaptation more powerfully than sustained hyperoxia [D: framing from the Efrati-group hypothesis literature; the paradox concept itself is mechanism-plausible but specific outcome trials at consumer pressures are sparse]

Hard vs. mild HBOT — the distinction that matters

This is the single most evidence-sensitive section on the page. The brand's positioning depends on getting this right.

Hard HBOT (medical): 2.0–3.0 ATA, 100% oxygen, hospital-grade chambers. FDA-cleared for 14 specific conditions including non-healing wounds, carbon monoxide poisoning, decompression sickness, radiation tissue damage, and severe anemia [A: regulatory fact verifiable in FDA + UHMS guidance + ECHM Consensus 2017]. Most published efficacy research occurred at 2.0+ ATA.

Mild HBOT / mHBOT (wellness): 1.3–1.5 ATA, room air or supplemental oxygen via concentrator. Most consumer chambers fall here.

The dose-response evidence is clear and pressure-dependent. Harch et al. 2022 Frontiers in Neurology (PMID 35370896) systematic review of HBOT for persistent post-concussion symptoms found statistically significant effects clustered at 1.5 ATA × 40 sessions and 2.0 ATA × 40 sessions [B: systematic review of mostly Efrati-group RCTs + replications, trending A given synthesis layer]. Studies at 1.3 ATA × fewer sessions showed weaker effects.

Bottom line: Consumer chambers at 1.3 ATA extrapolate from clinical work done at 1.5–2.0 ATA [D: the 1.3 ATA-specific RCT base is much thinner than chamber marketing implies]. The extrapolation may be valid, but it is not currently proven by 1.3 ATA-specific trial evidence. We say this directly because customers deserve to know it before they spend $15,000 on a chamber.

The research

Shai Efrati (Tel Aviv University / Sagol Center) led the landmark cognitive HBOT trials — Alzheimer's, post-stroke, post-TBI cognitive recovery, Long COVID, and most recently aging biomarkers [B: multiple Efrati-group RCTs across indications; Cohen's d 0.4–0.6 on cognitive endpoints. Honest caveat: most of the cognitive HBOT trial work is from this single group. Independent replication outside Israel is sparse. Treat findings as "plausible and provisionally accepted; awaiting independent replication"]. His work occurs at higher ATA than consumer chambers reach.

Paul Harch has spent decades on neurological HBOT applications, particularly traumatic brain injury and post-concussive syndrome [C: Harch 2017 mTBI + PTSD at 1.5 ATA replicates Boussi-Gross].

Jason Sonners runs the clinical hyperbaric practice many in this space consider the reference operation. His clinical observations on mild HBOT outcomes are widely cited; the formal trial evidence on consumer-pressure chambers is still maturing.

Cochrane counterweight. Bennett et al. 2012 [A: Cochrane systematic review of HBOT for TBI, PMID 23235612] found HBOT reduces risk of death in acute TBI but quality-of-life data was weak. The Cochrane is the conservative voice; cite alongside Harch 2022 to show both sides of the evidence base.

⚠️ Important Pass 3 caveat (Hadanny 2024 PTSD dose-response): In the PTSD dose-response analysis [C: Hadanny 2024 Frontiers in Neurology PMID 38882688], 30–39% of subjects experienced reversible exacerbation of emotional symptoms at the highest oxygen doses. Higher dose drove larger benefit AND larger adverse emotional response. This is a contraindication-adjacent finding worth knowing for HBOT-curious customers with trauma-adjacent indications.

The protocol

  • Hard HBOT (medical): 90 min at 2.0 ATA, 5 days/week, 40–60 session courses [B trending A at this dose]
  • Intermediate (1.5 ATA): 60 min at 1.5 ATA, 5 days/week, 40 sessions [B: strongest consumer-adjacent evidence]
  • Consumer mild (1.3 ATA): 60–90 min, 5 days/week course [D / mechanism-only at this pressure]
  • Sensation: Ear pressure during pressurization and depressurization — the only skill is Eustachian tube clearing
  • Contraindications: Untreated pneumothorax (absolute), recent ear surgery, certain chemotherapy regimens, severe COPD with CO2 retention. See Lin 2023 systematic review of HBOT adverse effects [B: PMC10232961] for the full safety profile.

The vocabulary

ATA (atmospheres absolute) — pressure unit; 1 ATA = sea level. Henry's Law — gas solubility scales with pressure. Hyperoxic-hypoxic paradox — Efrati-group hypothesis about oscillating O2 levels as adaptive trigger. Neovascularization / angiogenesis — formation of new blood vessels. VEGF — vascular endothelial growth factor. Stem cell mobilization — release of progenitor cells from marrow. Oxygen toxicity — real at high doses/durations; relevant at 2.0+ ATA for extended sessions. Off-label — clinical use beyond FDA-cleared indications.

What we look for in an oxygen supplier

Pressure capacity and stability matter most. A chamber that holds 1.5 ATA without drift, with a compressor quiet enough to use daily, with a documented emergency depressurization protocol, is a different product than a chamber that wobbles between 1.2 and 1.4 ATA in a noisy compressor enclosure. Concentrator quality (delivered O2 percentage), chamber material, and accessibility are the rest of the spec sheet. We require suppliers to articulate mechanism, cite research at the pressure they're selling, and surface the dose-evidence gap honestly. We don't carry chambers without clear pressure documentation, and we don't permit 1.3 ATA chambers to be marketed using 2.0 ATA Efrati-group trial evidence.

Light Exposure

Photobiomodulation. Specific wavelengths of red and near-infrared light driving mitochondrial function via cytochrome c oxidase.

The mechanism

Light at 660nm (red) and 810–850nm (near-infrared) penetrates skin to different depths — 660nm reaches surface tissues, NIR reaches muscle, joint, and bone (~3–5cm penetration). Photons get absorbed by cytochrome c oxidase (CCO), Complex IV of the mitochondrial electron transport chain [B: well-established mechanism per Hamblin body of work].

What happens next:

  • ATP production increases — the electron transport chain runs more efficiently
  • Inhibitory nitric oxide displaces from CCO, restoring oxidative phosphorylation
  • Reactive oxygen species (ROS) modulate to signaling levels — a small ROS spike triggers adaptive antioxidant response

This is biphasic. The dose has a defined therapeutic window: too little does nothing, too much erases the benefit. The contemporary better-evidenced range is approximately 2–30 J/cm² per body area per session [B: 2024 Frontiers in Medicine review PMC11358123 narrowing the earlier 4–60 J/cm² range from Huang/Sharma/Carroll/Hamblin 2011 PMID 22461763]. Below 2 J/cm², no effect. Past 30 J/cm², returns plateau. At 50–100 J/cm² per session, inhibitory effects emerge. This is the Arndt-Schulz curve, and it's the most-violated principle in consumer red light marketing.

The research

Michael Hamblin (Harvard, retired) is the foundational researcher in photobiomodulation. Hundreds of peer-reviewed papers across applications. If you cite one name in light therapy, cite Hamblin [B: foundational mechanism work + 2017 anti-inflammatory review PMID 28748217].

Hair growth in androgenetic alopecia is the strongest indication-specific evidence base. Multiple RCTs (Lanzafame 2013/2014 [B]) plus a 2017 meta-analysis (Afifi et al., 11 RCTs, 680 patients [A]) and a 2019 update (15 RCTs, 795 patients [A]) document significant effect. FDA-cleared device category.

Skin collagen / wrinkles: Wunsch & Matuschka 2014 Photomedicine and Laser Surgery PMID 24286286 [B] showed reduced wrinkles, increased dermal collagen density on ultrasonography over 30 sessions across 15 weeks.

Joint pain / musculoskeletal: multiple RCTs and meta-analyses support PBM for knee osteoarthritis, chronic low back pain, and tendinopathies [B].

Glen Jeffery (UCL) has done the most interesting recent work on red light and mitochondrial aging — particularly retinal applications and the mitochondrial diurnal sensitivity to specific wavelengths.

Transcranial PBM for depression is the most-discussed emerging area. Cassano 2018 ELATED-2 pilot RCT [C] showed measurable antidepressant effect; Iosifescu 2022 ELATED-3 multicenter [C] replicated at smaller effect size; two 2023 meta-analyses provide synthesis-layer support. The body of work is small but coherent. Treat as emerging support, not established treatment.

Praveen Arany, past president of NAALT (North American Association for Photobiomodulation Therapy), bridges clinical and basic-science communities.

The protocol

  • Distance from panel: 6–12 inches for therapeutic dose
  • Duration: 10–20 minutes per body area at single-region irradiance; 5–10 minutes for whole-body at high irradiance
  • Dose: 2–30 J/cm² per body area per session is the contemporary better-evidenced therapeutic window [B: 2024 update]. Earlier reviews cite 4–60 J/cm²; the field has narrowed.
  • Frequency: 3–5× weekly
  • Eye protection: Recommended for direct exposure to high-irradiance panels, especially extended sessions

The vocabulary

Photobiomodulation (PBM) — preferred scientific term; "red light therapy" is consumer shorthand. Cytochrome c oxidase (CCO) — Complex IV of the mitochondrial electron transport chain; the molecular target for PBM. Wavelength (nm) — nanometer measurement of light frequency. Irradiance (mW/cm²) — power density at distance. Dose (J/cm²) — total energy delivered per unit area. Biphasic dose response / Arndt-Schulz curve — the more-is-not-better principle. Coherent vs. non-coherent light — laser vs. LED; both produce PBM effects, LED is consumer-scale. NIR vs. MIR/FIR — near-infrared (PBM mechanism) vs. mid/far-infrared (heat mechanism). Don't conflate.

What we look for in a light supplier

Irradiance at distance, not at surface. Manufacturers love to cite at-surface irradiance because the number is largest. Real-use irradiance is measured at 6–12 inches. Specific wavelengths (the standard premium configuration is 660nm + 850nm dual-wavelength), LED count and power per LED, EMF rating at occupant position, beam angle, and third-party irradiance verification (independent meter readings, not manufacturer claims) are the spec sheet. We require suppliers to cite the research behind their dose claims at the contemporary 2–30 J/cm² window, weighted per established frameworks. We don't carry panels without third-party verification.

The Umbrella: Hormesis

All four exposures share a single principle. They're dosed stressors. Cold, heat, low oxygen, and light energy at therapeutic dose — all challenge the body within a window where adaptation occurs and damage doesn't.

This is hormesis, from the Greek hormaein, "to excite into action." Too little stimulus produces no adaptation. Too much produces injury. The protocol window in the middle produces the upward shift in capacity. Hormesis as a general principle is [A]-grade in biology (Mark Mattson's foundational neuroscience work + decades of replication across organisms and stressor types). The specific applications to each modality vary in evidence strength, which is why we weight them individually above.

This principle is also the reason Exposure Method exists in its current form. The recovery industry has decades of accumulated language that treats these protocols as wellness — soft, vague, vibes-based. They're not. They're stress applications calibrated to dose. The hardware that delivers them deserves to be evaluated on engineering, not energy.

Before You Buy

We do pre-purchase consultations for every product over $2,500 on this site. Forty-five minutes, free, with the founder. We'll review your training history, your existing recovery infrastructure, your space, your budget, and the realistic place a new piece of equipment fits in your protocol. Then we'll tell you what we'd buy in your situation — including, often, that you should buy less than you were planning, or different than you were looking at.

This is not a sales call. We make money when you buy the right thing, not when you buy the most thing.

Book a 45-min consultation →